Y-mAbs Therapeutics (YMAB) Set to Announce Quarterly Earnings on Tuesday

Y-mAbs Therapeutics (NASDAQ:YMAB) will be announcing its earnings results after the market closes on Tuesday, May 7th. Analysts expect the company to announce earnings of ($0.12) per share for the quarter. Y-mAbs Therapeutics has set its FY 2024 guidance at EPS.Persons interested in participating in the company’s earnings conference call can do so using this link.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings results on Thursday, February 29th. The company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.17. Y-mAbs Therapeutics had a negative return on equity of 20.72% and a negative net margin of 25.26%. The firm had revenue of $23.36 million during the quarter, compared to analysts’ expectations of $21.72 million. On average, analysts expect Y-mAbs Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Y-mAbs Therapeutics Stock Performance

Shares of YMAB stock traded down $0.22 during mid-day trading on Tuesday, hitting $15.28. The company’s stock had a trading volume of 71,491 shares, compared to its average volume of 392,271. Y-mAbs Therapeutics has a 52-week low of $4.60 and a 52-week high of $20.90. The business has a 50-day moving average price of $15.72 and a 200 day moving average price of $10.65. The stock has a market cap of $668.96 million, a price-to-earnings ratio of -31.63 and a beta of 0.74.

Wall Street Analysts Forecast Growth

Several analysts recently commented on YMAB shares. Canaccord Genuity Group lifted their price objective on Y-mAbs Therapeutics from $22.00 to $26.00 and gave the stock a “buy” rating in a report on Monday, March 4th. HC Wainwright lifted their price objective on Y-mAbs Therapeutics from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Wednesday, March 6th. Wedbush reaffirmed an “outperform” rating and issued a $18.00 price objective (up previously from $12.00) on shares of Y-mAbs Therapeutics in a report on Monday, February 12th. Finally, BMO Capital Markets lifted their price objective on Y-mAbs Therapeutics from $16.00 to $26.00 and gave the stock an “outperform” rating in a report on Monday, March 4th. Two investment analysts have rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $16.57.

Insider Buying and Selling at Y-mAbs Therapeutics

In other news, SVP Vignesh Rajah sold 1,711 shares of the business’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $16.53, for a total value of $28,282.83. Following the transaction, the senior vice president now directly owns 33,889 shares in the company, valued at $560,185.17. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 21.50% of the stock is currently owned by corporate insiders.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.